ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/gp100
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/gp100
5
trial(s) found.
NCT07203391
Advanced
Phase 1
Recruiting
TRIUMPH
- Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
PI3K delta inhibitor
bispecfic T-cell engager,gp100-targeting
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT07063875
Advanced
Phase 1 / Phase 2
Recruiting
Supplementing With IL-2 to Verifiably eRadicate Radiological Progression (
SILVER
)
Aldesleukin
IL-2 variant
Tebentafusp
bispecfic T-cell engager,gp100-targeting
cancer therapy
cancer therapy,IL-2-targeting
cancer therapy,gp100-targeting
cytokine therapy
cytokine therapy,IL-2-targeting
immuno-oncology therapy,IL-2-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ bispecfic T-cell engager,gp100-targeting
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT05785754
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (
DCSZ11-101
)
anti-CD93 monoclonal antibody
+ bispecfic T-cell engager,gp100-targeting
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2076 - Wahroonga - Sydney Adventist Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
4812 - Townsville - Townsville University Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05549297
Advanced
Phase 3
Recruiting
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM) (
IMCgp100-203
)
anti-PD-1 monoclonal antibody
bispecfic T-cell engager,gp100-targeting
Melanoma
NOT Mucosal melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
NCT04262466
Advanced
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers (
IMC-F106C-101
)
bispecific T-cell engager,PRAME-targeting
+ bispecfic T-cell engager,gp100-targeting
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Recruitment Country and State
NSW (5)
VIC (5)
QLD (2)
WA (2)
SA (1)
NZ (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (2)
Phase 3 (1)
Trial Type
Advanced (5)
Cancer Therapy Class
gp100
100%
PD-1
60%
PD-1/PD-L1
60%
PI3K delta
20%
IL-2
20%
CD93
20%
PRAME
20%
VEGF
20%
Facility
3004 - Melbourne, Southbank - Alfred Health (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2031 - Randwick - Scientia Clinical Research Ltd (2)
6009 - Nedlands - Linear Clinical Research (2)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (2)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4812 - Townsville - Townsville University Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
Cancer Type
Cancer
Solid tumour
Melanoma
Uveal melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy